GC Pharma, the most likely company to produce Covivak
By Nho, Byung Chul | translator Choi HeeYoung
21.07.06 11:10:00
°¡³ª´Ù¶ó
0
MPC to acquire shares in Pharm Bio-tech, Russia
Technology transfer by September
Production and sales are expected around October
According to industries, MPC, which is a South Korean corporation to introduce Covivak, recently signed a contract with Pharm Bio-tech, a Russian company that has rights to produce and publish in Russia, to acquire shares (37.5%). Among the domestic companies that invested in securing the stake, Wellbiotec, HumanN, and Nexton Bio became Pharm Bio-tech shareholders.
MPC is also expected to establish a joint venture for Pharm Bio-tech and Covivak production, sales, and distribution in Korea to run vaccine businesses for ASEAN countries.
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)